

Ting-Bo Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7249316/publications.pdf>

Version: 2024-02-01

174
papers

9,843
citations

53794

45
h-index

45317

90
g-index

184
all docs

184
docs citations

184
times ranked

17593
citing authors

#	ARTICLE	IF	CITATIONS
1	Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. <i>BMJ</i> , The, 2020, 369, m1443.	6.0	1,226
2	A Deep Learning System to Screen Novel Coronavirus Disease 2019 Pneumonia. <i>Engineering</i> , 2020, 6, 1122-1129.	6.7	858
3	Construction of a human cell landscape at single-cell level. <i>Nature</i> , 2020, 581, 303-309.	27.8	695
4	Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences. <i>Transplantation</i> , 2008, 85, 1726-1732.	1.0	400
5	Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. <i>Gut</i> , 2019, 68, 2019-2031.	12.1	230
6	Hypoxia-inducible factor-1 α /interleukin-1 β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. <i>Hepatology</i> , 2018, 67, 1872-1889.	7.3	216
7	Wnt/ β -catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1 α signaling. <i>Carcinogenesis</i> , 2013, 34, 962-973.	2.8	208
8	Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. <i>Genes and Development</i> , 2017, 31, 247-259.	5.9	207
9	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	17.1	191
10	Hepatic RIG-I Predicts Survival and Interferon- γ Therapeutic Response in Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 49-63.	16.8	182
11	The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. <i>Nature</i> , 2020, 580, 530-535.	27.8	171
12	Macrophage-Induced Tumor Angiogenesis Is Regulated by the TSC2-mTOR Pathway. <i>Cancer Research</i> , 2012, 72, 1363-1372.	0.9	154
13	Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 138.	17.1	148
14	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105631.	4.0	141
15	Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer. <i>Oncogene</i> , 2018, 37, 6105-6118.	5.9	119
16	VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 83.	17.0	118
17	Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1. <i>Cancer Research</i> , 2017, 77, 4868-4880.	0.9	116
18	Cutting Edge: Notch Signaling Promotes the Plasticity of Group-2 Innate Lymphoid Cells. <i>Journal of Immunology</i> , 2017, 198, 1798-1803.	0.8	115

#	ARTICLE	IF	CITATIONS
19	Practice Patterns and Perioperative Outcomes of Laparoscopic Pancreaticoduodenectomy in China. <i>Annals of Surgery</i> , 2021, 273, 145-153.	4.2	98
20	Hypoxia-inducible factor-2 β promotes tumor progression and has crosstalk with Wnt/ β -catenin signaling in pancreatic cancer. <i>Molecular Cancer</i> , 2017, 16, 119.	19.2	97
21	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 1580-1590.	3.4	94
22	The Evolving Landscape of Noncanonical Functions of Metabolic Enzymes in Cancer and Other Pathologies. <i>Cell Metabolism</i> , 2021, 33, 33-50.	16.2	93
23	Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. <i>Molecular Cancer</i> , 2021, 20, 44.	19.2	93
24	Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. <i>Scientific Reports</i> , 2016, 6, 23269.	3.3	90
25	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β -catenin/TCF complex association via FOXO3a activation. <i>Oncotarget</i> , 2015, 6, 10350-10365.	1.8	84
26	A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. <i>Cell Research</i> , 2015, 25, 997-1012.	12.0	84
27	A non-canonical cGAS \rightarrow STING \rightarrow PERK pathway facilitates the translational program critical for senescence and organ fibrosis. <i>Nature Cell Biology</i> , 2022, 24, 766-782.	10.3	84
28	Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. <i>Molecular Cancer</i> , 2021, 20, 50.	19.2	83
29	Duct-to-Mucosa vs Invagination for Pancreaticojejunostomy after Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial from a Single Surgeon. <i>Journal of the American College of Surgeons</i> , 2016, 222, 10-18.	0.5	78
30	Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 237-243.	7.2	78
31	CT Quantification and Machine-learning Models for Assessment of Disease Severity and Prognosis of COVID-19 Patients. <i>Academic Radiology</i> , 2020, 27, 1665-1678.	2.5	74
32	CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production. <i>Cell Death and Disease</i> , 2018, 9, 905.	6.3	69
33	Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 564-574.	3.4	68
34	Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. <i>Radiation Oncology</i> , 2018, 13, 188.	2.7	67
35	Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. <i>Biomaterials</i> , 2019, 192, 590-600.	11.4	61
36	Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 196-203.	4.1	61

#	ARTICLE	IF	CITATIONS
37	Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. <i>World Journal of Gastroenterology</i> , 2018, 24, 3500-3512.	3.3	58
38	WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. <i>Cancer Letters</i> , 2015, 361, 218-225.	7.2	55
39	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 227-252.	1.5	55
40	Fully end-to-end deep-learning-based diagnosis of pancreatic tumors. <i>Theranostics</i> , 2021, 11, 1982-1990.	10.0	54
41	Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2020, 22, 821-832.	0.3	54
42	Contrast-enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A two-center study. <i>Clinical and Translational Medicine</i> , 2020, 10, e111.	4.0	53
43	Group 2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression. <i>Hepatology</i> , 2021, 74, 2526-2543.	7.3	53
44	Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. <i>Gut</i> , 2022, 71, 1176-1191.	12.1	52
45	Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution potentially related to Furin cleavage site. <i>Emerging Microbes and Infections</i> , 2020, 9, 1474-1488.	6.5	51
46	NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. <i>Nature Communications</i> , 2021, 12, 4536.	12.8	51
47	Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity. <i>Molecular Cell</i> , 2021, 81, 4147-4164.e7.	9.7	51
48	Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. <i>Scientific Reports</i> , 2015, 5, 13664.	3.3	49
49	piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. <i>Nature Cell Biology</i> , 2020, 22, 425-438.	10.3	49
50	G protein-coupled estrogen receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis. <i>Cancer Letters</i> , 2016, 382, 195-202.	7.2	47
51	One-stage laproendoscopic procedure versus two-stage procedure in the management for gallstone disease and biliary duct calculi: a systemic review and meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 3582-3590.	2.4	47
52	Liquid biopsy in pancreatic cancer: the beginning of a new era. <i>Oncotarget</i> , 2018, 9, 26900-26933.	1.8	47
53	Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. <i>British Journal of Cancer</i> , 2019, 121, 786-795.	6.4	47
54	Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. <i>Liver Transplantation</i> , 2005, 11, 1527-1532.	2.4	46

#	ARTICLE	IF	CITATIONS
55	Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 152.	3.7	46
56	Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway. <i>Journal of Biological Chemistry</i> , 2018, 293, 1178-1191.	3.4	45
57	USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. <i>Cancer Letters</i> , 2018, 436, 129-138.	7.2	45
58	Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1 α -VEGF mediated angiogenesis. <i>Cancer Letters</i> , 2014, 355, 281-287.	7.2	44
59	ALK phosphorylates SMAD4 on tyrosine to disable TGF- β 2 tumour suppressor functions. <i>Nature Cell Biology</i> , 2019, 21, 179-189.	10.3	41
60	Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 367-371.	4.0	41
61	ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial \rightarrow mesenchymal transition. <i>Cancer Letters</i> , 2016, 377, 140-148.	7.2	40
62	A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. <i>Hpb</i> , 2020, 22, 795-808.	0.3	39
63	The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. <i>Cancer Letters</i> , 2016, 380, 98-105.	7.2	38
64	A redox-sensitive, oligopeptide-guided, self-assembling, and efficiency-enhanced (ROSE) system for functional delivery of microRNA therapeutics for treatment of hepatocellular carcinoma. <i>Biomaterials</i> , 2016, 104, 192-200.	11.4	37
65	TBK1-Mediated DRP1 Targeting Confers Nucleic Acid Sensing to Reprogram Mitochondrial Dynamics and Physiology. <i>Molecular Cell</i> , 2020, 80, 810-827.e7.	9.7	35
66	AFP (alpha fetoprotein): Who are you in gastrology?. <i>Cancer Letters</i> , 2015, 357, 43-46.	7.2	34
67	The implementation of an enhanced recovery after surgery (ERAS) program following pancreatic surgery in an academic medical center of China. <i>Pancreatology</i> , 2016, 16, 665-670.	1.1	31
68	Roles of Sphincter of Oddi Laxity in Bile Duct Microenvironment in Patients with Cholangiolithiasis: From the Perspective of the Microbiome and Metabolome. <i>Journal of the American College of Surgeons</i> , 2016, 222, 269-280.e10.	0.5	31
69	Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 279.	8.6	31
70	Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats. <i>Liver Transplantation</i> , 2012, 18, 696-706.	2.4	30
71	Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 347.	2.6	29
72	External validation of alternative fistula risk score (a-FRS) for predicting pancreatic fistula after pancreatoduodenectomy. <i>Hpb</i> , 2020, 22, 58-66.	0.3	28

#	ARTICLE	IF	CITATIONS
73	Contingency management strategies of the Nursing Department in centralized rescue of patients with coronavirus disease 2019. <i>International Journal of Nursing Sciences</i> , 2020, 7, 139-142.	1.3	28
74	Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage. <i>Frontiers in Immunology</i> , 2021, 12, 702580.	4.8	27
75	The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 775507.	3.7	27
76	Meta-analysis of invagination and duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: An update. <i>International Journal of Surgery</i> , 2016, 36, 240-247.	2.7	25
77	Associating liver partition and portal vein ligation versus 2-stage hepatectomy. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overloc</i>	1.0	25
78	Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. , 2022, 10, e003982.		25
79	B7â€H5/<scp>CD</scp>28H is a coâ€stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. <i>Cancer Science</i> , 2019, 110, 530-539.	3.9	24
80	ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-16.	1.5	21
81	Association of Modifiedâ€FOLFIRINOXâ€Regimenâ€Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. <i>Oncologist</i> , 2019, 24, 301.	3.7	21
82	Molecular Profilingâ€Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 532403.	2.8	20
83	Interplay between myeloid-derived suppressor cells (MDSCs) and Th17 cells: foe or friend?. <i>Oncotarget</i> , 2016, 7, 35490-35496.	1.8	20
84	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 56.	8.6	20
85	Longâ€term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1552-1562.	2.8	19
86	Non-cytomembrane PD-L1: An atypical target for cancer. <i>Pharmacological Research</i> , 2021, 170, 105741.	7.1	19
87	Impact of enhanced recovery protocols after pancreatoduodenectomy: meta-analysis. <i>British Journal of Surgery</i> , 2022, 109, 256-266.	0.3	19
88	Fate mapping analysis reveals a novel murine dermal migratory Langerhans-like cell population. <i>ELife</i> , 2021, 10, .	6.0	18
89	OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both<i>in vitro</i> and<i>in vivo</i>. <i>Oncotarget</i> , 2015, 6, 26230-26241.	1.8	18
90	Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. <i>BMC Cancer</i> , 2022, 22, 293.	2.6	18

#	ARTICLE	IF	CITATIONS
91	Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. <i>Cellular and Molecular Immunology</i> , 2020, 17, 677-679.	10.5	17
92	Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression. <i>Frontiers in Immunology</i> , 2020, 11, 2076.	4.8	17
93	Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas. <i>Frontiers in Medicine</i> , 2020, 7, 584250.	2.6	16
94	Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 357-363.	2.4	15
95	Calreticulin couples with immune checkpoints in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 36-44.	4.0	15
96	Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. <i>EBioMedicine</i> , 2022, 78, 103958.	6.1	15
97	Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. <i>Science Advances</i> , 2022, 8, .	10.3	15
98	A PEGylated megamer-based microRNA delivery system activatable by stepwise microenvironment stimulation. <i>Chemical Communications</i> , 2019, 55, 9363-9366.	4.1	14
99	Tumor-triggered personalized microRNA cocktail therapy for hepatocellular carcinoma. <i>Biomaterials Science</i> , 2020, 8, 6579-6591.	5.4	14
100	Sphincter of Oddi laxity alters bile duct microbiota and contributes to the recurrence of choledocholithiasis. <i>Annals of Translational Medicine</i> , 2020, 8, 1383-1383.	1.7	14
101	Subtyping for pancreatic cancer precision therapy. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 482-494.	8.7	14
102	Role of IL-21 signaling pathway in transplant-related biology. <i>Transplantation Reviews</i> , 2016, 30, 27-30.	2.9	13
103	The protein phosphatase PPM1A dephosphorylates and activates YAP to govern mammalian intestinal and liver regeneration. <i>PLoS Biology</i> , 2021, 19, e3001122.	5.6	13
104	Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. <i>World Journal of Gastroenterology</i> , 2019, 25, 4749-4763.	3.3	13
105	Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth. <i>Nature Metabolism</i> , 2022, 4, 239-253.	11.9	13
106	Oncolytic virotherapy in hepatocellular carcinoma and pancreatic cancer: The key to breaking the log jam?. <i>Cancer Medicine</i> , 2020, 9, 2943-2959.	2.8	12
107	Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. <i>Molecular Oncology</i> , 2020, 14, 1966-1977.	4.6	12
108	Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 485-492.	1.1	12

#	ARTICLE	IF	CITATIONS
109	Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. <i>Cancer Letters</i> , 2022, 539, 215722.	7.2	12
110	Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. <i>Radiation Oncology</i> , 2016, 11, 138.	2.7	11
111	Laparoscopic Spleen-Preserving Distal Pancreatectomy (LSPDP) with Preservation of Splenic Vessels: An Inferior-Posterior Approach. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	11
112	Surgical management and outcome of grade-C pancreatic fistulas after pancreaticoduodenectomy: A retrospective multicenter cohort study. <i>International Journal of Surgery</i> , 2019, 68, 27-34.	2.7	11
113	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. <i>Npj Precision Oncology</i> , 2020, 4, 29.	5.4	11
114	Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 94.	17.1	11
115	Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4088-4088.	1.6	11
116	Novel deep learning radiomics model for preoperative evaluation of hepatocellular carcinoma differentiation based on computed tomography data. <i>Clinical and Translational Medicine</i> , 2021, 11, e570.	4.0	11
117	Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 85.	9.1	11
118	Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. , 2022, 10, e004129.		11
119	Surgical resection and outcome of pancreatic cystic neoplasms in China: analysis of a 16-year experience from a single high-volume academic institution. <i>World Journal of Surgical Oncology</i> , 2014, 12, 228.	1.9	9
120	Pancreas-preserving management of grade-C pancreatic fistula and a novel bridging technique for repeat pancreaticojejunostomy: An observational study. <i>International Journal of Surgery</i> , 2018, 52, 243-247.	2.7	9
121	The AKT-independent MET-ATPase-MTOR axis suppresses liver cancer vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 122.	17.1	9
122	Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. <i>Oncogene</i> , 2021, 40, 3136-3151.	5.9	9
123	Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2022, 20, 49.	4.4	9
124	Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 560-560.	1.6	9
125	Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy. <i>EBioMedicine</i> , 2022, 79, 103987.	6.1	9
126	Esophageal neuroendocrine carcinoma complicated with unexpected hyperprolactin. <i>Medicine (United States)</i> , 2018, 97, e12219.	1.0	8

#	ARTICLE	IF	CITATIONS
127	Patients with pancreatic cystic neoplasms can benefit from management of multidisciplinary team: Experience from a Chinese academic center. <i>Pancreatology</i> , 2018, 18, 799-804.	1.1	8
128	Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell. , 2021, 9, e002823.		8
129	Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies. <i>Biotechnology Journal</i> , 2021, 16, e2100207.	3.5	8
130	One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, , 188696.	7.4	8
131	Regulatory T cells contribute to the immunoregulatory effect on graft versus host reaction after liver transplantation in donor-dominant one-way MHC matching rats. <i>Transplant Immunology</i> , 2009, 20, 232-237.	1.2	7
132	A hospital-to-home evaluation of an enhanced recovery protocol for elective pancreaticoduodenectomy in China. <i>Medicine (United States)</i> , 2017, 96, e8206.	1.0	7
133	Liver Transplantation from Voluntary Organ Donor System in China: A Comparison between DBD and DCD Liver Transplants. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	1.5	7
134	Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective. <i>Oncotarget</i> , 2020, 9, 1818438.	4.6	7
135	Carcinoma of the pancreas: comprehensive clinicopathological and molecular characterization. <i>Hpb</i> , 2020, 22, 1590-1595.	0.3	7
136	Immunosuppressants in Liver Transplant Recipients With Coronavirus Disease 2019: Capability or Catastrophe? A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 756922.	2.6	7
137	Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 862154.	2.8	7
138	Role of Collateral Venous Circulation in Prevention of Sinistral Portal Hypertension After Superior Mesenteric-Portal Vein Confluence Resection during Pancreaticoduodenectomy: a Single-Center Experience. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2054-2061.	1.7	6
139	Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule. <i>Journal of Controlled Release</i> , 2020, 317, 67-77.	9.9	6
140	Outcomes of liver transplantation using moderately steatotic liver from donation after cardiac death (DCD). <i>Annals of Translational Medicine</i> , 2020, 8, 1188-1188.	1.7	6
141	Oncolytic virus combined with traditional treatment versus traditional treatment alone in patients with cancer: a meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1901-1913.	2.2	6
142	Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. <i>Hpb</i> , 2021, 23, 1427-1438.	0.3	6
143	Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Review of Their Genetic Characteristics and Mouse Models. <i>Cancers</i> , 2021, 13, 5296.	3.7	6
144	mRNA vaccine development for cholangiocarcinoma: a precise pipeline. <i>Military Medical Research</i> , 2022, 9, .	3.4	6

#	ARTICLE	IF	CITATIONS
145	Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity. , 2022, 10, e005065.		6
146	Dermatological Disorders following Liver Transplantation: An Update. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-9.	1.9	5
147	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	2.8	5
148	Pancreatic tumor initiation: the potential role of IL-33. Signal Transduction and Targeted Therapy, 2021, 6, 204.	17.1	5
149	A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 728476.	2.3	5
150	Liver Transplantation for Alcohol-Related Liver Disease (ARLD): An Update on Controversies and Considerations. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-6.	1.9	4
151	Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity. Frontiers in Oncology, 2020, 10, 1289.	2.8	4
152	A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study. BMC Cancer, 2021, 21, 280.	2.6	4
153	Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. American Journal of Translational Research (discontinued), 2019, 11, 473-485.	0.0	4
154	OSI-027 modulates acute graft-versus-host disease after liver transplantation in a rat model. Liver Transplantation, 2017, 23, 1186-1198.	2.4	3
155	Combinational therapy targeting the MET-mTOR-ROS loop disrupts mitochondrial autoregulatory machinery of liver cancer. Clinical and Translational Medicine, 2020, 10, e237.	4.0	3
156	Multiplex imaging reveals the architecture of the tumor immune microenvironment. Cancer Biology and Medicine, 2021, 18, 949-954.	3.0	3
157	RCAN1-mediated calcineurin inhibition as a target for cancer therapy. Molecular Medicine, 2022, 28, .	4.4	3
158	Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, e16131-e16131.	1.6	3
159	Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study. Frontiers in Pharmacology, 2020, 11, 1252.	3.5	2
160	Perioperative mental evaluation and intervention for lung transplantation in elderly patients with COVID-19. Psychiatry and Clinical Neurosciences, 2020, 74, 568-569.	1.8	2
161	Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the Tj ETQq1 1 01784314 rgBT /Over	1.7	2
162	<p>Stereotactic body radiotherapy as the initial treatment for hepatocellular carcinoma with extensive inferior vena cava and atrium tumor thrombus</p>. OncoTargets and Therapy, 2019, Volume 12, 5299-5303.	2.0	1

#	ARTICLE	IF	CITATIONS
163	Vascular reconstruction of segmental intestinal grafts using autologous internal iliac vessels. Gastroenterology Report, 2021, 9, 350-356.	1.3	1
164	Gallbladder Adenosquamous Cancer with Situs Inversus Totalis: A Case Report and Literature Review. OncoTargets and Therapy, 2021, Volume 14, 4299-4304.	2.0	1
165	Response to Comment on "Lung Transplantation for Elderly Patients With End-stage COVID-19 Pneumonia" Annals of Surgery, 2021, 274, e831.	4.2	1
166	Recent controversies in liver transplantation. Journal of Patan Academy of Health Sciences, 2020, 7, 98-102.	0.2	1
167	Acute Decompensated Liver: When to Transplant?. , 0, , .		1
168	A Case Report on Successful Liver Transplantation from a Donor with Polycystic Liver. Indian Journal of Surgery, 2014, 76, 405-407.	0.3	0
169	Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery, 2018, 164, 1392.	1.9	0
170	Development of a radiomics nomogram based on the CE-CT features to predict the survival of upfront resectable patients with pancreatic head cancer and suspected venous invasion.. Journal of Clinical Oncology, 2019, 37, e15760-e15760.	1.6	0
171	Effect of ARK5 on the anti-tumour activity of OSI-027 via regulation of epithelial-mesenchymal transition in pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, e15758-e15758.	1.6	0
172	Pancreatic cancer: Assessment of neoadjuvant chemotherapy outcome based on radiomics of pretreatment computed tomography.. Journal of Global Oncology, 2019, 5, 56-56.	0.5	0
173	Abstract CT546: A phase 2, multicenter study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in patients with HCC at high risk of recurrence after curative resection. Cancer Research, 2022, 82, CT546-CT546.	0.9	0
174	<i>FAT1 </i>mutations in colorectal cancer patients are associated with the therapeutic benefit of immunotherapy.. Journal of Clinical Oncology, 2022, 40, e15523-e15523.	1.6	0